Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

% Price Oscillator

Score

-0.45

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 6 85.8 0.83% 2.50% 37.2% -5.3% 175.5%
SHORT 7 43.7 0.14% 0.17% 2.3% -12.4% -72.0%

Summary

Technical Analysis


The Percentage Price Oscillator (PPO) is a momentum oscillator that measures the difference between two moving averages as a percentage of the larger moving average.

Calculation: Percentage Price Oscillator (PPO):
1) PPO Line: {(12-day EMA - 26-day EMA)/26-day EMA} x 100;
2) Signal Line: 9-day EMA of PPO;
3) Histogram: PPO - Signal Line;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

% Price Oscillator

Download
Company Close Change(%) Volume Value Signal
VIVO Meridian Bioscience 8.16 9.2 1,886,706 3.2 BULLISH
STAA Staar Surgical 31.05 8 1,662,302 1.64 BULLISH
KPTI Karyopharm Therapeutics 15.38 7 1,860,063 0.19 BULLISH
ORBC Orbcomm 3.44 4.2 2,627,367 0.38 BULLISH
HSII Heidrick & Struggles 22.2 3.8 207,252 2.08 BULLISH
EZPW Ezcorp Inc 4.79 2.4 1,002,907 0.23 BULLISH
WIRE Encore Wire 50.87 2.3 196,575 21.09 BULLISH
SBLK Star Bulk Carriers 8.18 2.1 545,828 1.45 BULLISH
VNET 21Vianet 15.23 1.9 1,042,902 1.56 BULLISH
LMNX Luminex Corporation 23.59 1.5 569,111 0.44 BULLISH